Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2017 Mar 20:13:341-343.
doi: 10.2147/TCRM.S130816. eCollection 2017.

Second-line afatinib administration in an elderly patient with squamous cell carcinoma

Wolfgang Hohenforst-Schmidt  1 , Paul Zarogoulidis  2 , Michael Steinheimer  1 , Naim Benhassen  3 , Chrysanthi Sardeli  4 , Nikos Stalikas  2 , Melpomeni Toitou  2 , Haidong Huang  5
Affiliations
Case Reports

Second-line afatinib administration in an elderly patient with squamous cell carcinoma

Wolfgang Hohenforst-Schmidt et al. Ther Clin Risk Manag. .

Abstract

Introduction: The majority of cases of lung cancer are still diagnosed at a late stage. At this stage, palliative therapeutic options including nonspecific cytotoxic drugs, targeted therapy, or immunotherapy can be utilized. In 2016, immunotherapy was approved in Europe for squamous cell carcinoma and adenocarcinoma. Moreover, afatinib was also approved as second-line therapy for squamous cell carcinoma.

Case report: This article presents a case of a 76-year-old male with squamous cell carcinoma who received nab-paclitaxel as first-line therapy, and his treatment was switched to the tyrosine kinase inhibitor afatinib (40 mg) after disease progression with left lung atelectasis. After receiving afatinib for only 28 days, the atelectasis resolved. No adverse effects were observed from the afatinib therapy.

Discussion: In this case, afatinib 40 mg proved to be an effective alternative treatment for an elderly patient. Treatment choice should be based on the performance status of the patient, cost-effectiveness, and drug treatment guidelines.

Keywords: EGFR; afatinib; lung cancer.

PubMed Disclaimer

Conflict of interest statement

Disclosure Paul Zarogoulidis is a member of the advisory board of Boehringer Ingelheim® Greece for Oncology agents. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Left lung atelectasis (during abraxane, last therapy session); white arrow indicates the central mass to the left main bronchus.
Figure 2
Figure 2
Computed tomography scan of the thorax (during abraxane); the left lung is totally collapsed (white arrow).
Figure 3
Figure 3
After 28 days under afatinib 40 mg (the mass has started to shrink and the left lung to inflate, white arrow).
Figure 4
Figure 4
After 65 days from the afatinib 40 mg administration (white arrow indicates the part of the left lower lobe that has been inflated and red arrow indicates the central mass that used to totally block the left lung).
See this image and copyright information in PMC

References

    1. Kanodra NM, Pope C, Halbert CH, Silvestri GA, Rice LJ, Tanner NT. Primary care provider and patient perspectives on lung cancer screening. A qualitative study. Ann Am Thorac Soc. 2016;13(11):1977–1982. - PubMed
    1. Henschke CI, Yip R, Smith JP, et al. CT screening for lung cancer: part-solid nodules in baseline and annual repeat rounds. AJR Am J Roentgenol. 2016;207(6):1176–1184. - PubMed
    1. Domvri K, Zarogoulidis P, Darwiche K, et al. Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy. J Cancer. 2013;4(9):736–754. - PMC - PubMed
    1. Zarogoulidis K, Zarogoulidis P, Darwiche K, et al. Treatment of non-small cell lung cancer (NSCLC) J Thorac Dis. 2013;5(Suppl 4):S389–S396. - PMC - PubMed
    1. Stratakos G, Gerovasili V, Dimitropoulos C, et al. Survival and quality of life benefit after endoscopic management of malignant central airway obstruction. J Cancer. 2016;7(7):794–802. - PMC - PubMed

Publication types